Ken Griffin’s NeuroSense Therapeutics NRSN Stock Holding History

Ken Griffin’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-149,243	Closed	-$282K	–	13677
2025 Q2	$282K	Buy	+149,243	New	+$216K	﹤0.01%	9946
2025 Q1	–	Sell	-253,997	Closed	-$305K	–	15248
2024 Q4	$305K	Buy	253,997 +219,717	+641%	+$253K	﹤0.01%	9622
2024 Q3	$43.5K	Buy	+34,280	New	+$32.6K	﹤0.01%	12063
2023 Q4	–	Sell	-11,702	Closed	-$8.78K	–	14920
2023 Q3	$8.78K	Buy	+11,702	New	+$12.3K	﹤0.01%	13160
2022 Q1	–	Sell	-55,119	Closed	-$135K	–	14259
2021 Q4	$135K	Buy	+55,119	New	+$168K	﹤0.01%	12396

Other funds holding NRSN

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Ken Griffin's NRSN Position: Q3 2025 in Review

Ken Griffin sold out of NeuroSense Therapeutics (NRSN) in Q3 2025, closing a stake of 149,243 shares — an estimated $282K sold.

Ken Griffin first reported a position in NRSN in Q4 2021 and held it in 5 quarters. The position peaked at $305K in Q4 2024. 10 funds tracked by Wall St. Rank hold NRSN as of Q3 2025.

Ken Griffin reported no remaining NeuroSense Therapeutics position as of Q3 2025 after selling out during the quarter.
Ken Griffin sold 149,243 NeuroSense Therapeutics shares in Q3 2025, an estimated $282K.
Ken Griffin first reported a position in NeuroSense Therapeutics in Q4 2021 and held it in 5 quarters.
Ken Griffin's NeuroSense Therapeutics position peaked at $305K in Q4 2024.
10 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.